Department Medical Oncology, Instituto Catalán de Oncología, L'Hospitalet de Llobregat, Av. Gran Vía 199-203, 0898, Barcelona, Spain.
Department Palliative Care, Hospital Germans Trias I Pujol, Instituto Catalán de Oncología, Badalona, Spain.
Clin Transl Oncol. 2017 Nov;19(11):1293-1302. doi: 10.1007/s12094-017-1682-6. Epub 2017 Jun 13.
Pancreatic ductal adenocarcinoma (PDAC) is one of the cancers with poorest prognosis and represents the third leading cause of cancer-related deaths in Western countries. Despite advances in diagnostic procedures and treatment, diagnosis is made in most cases when the disease is locally advanced or metastatic. Supportive care aims to improve symptoms, reduce hospital admission rates, and preserve quality of life. Proper symptomatic management is critical to allow administration of chemotherapy and radiotherapy. Symptomatic management should be accomplished in a multidisciplinary fashion. Its primary aims include relief of biliary or duodenal obstruction, prevention and/or treatment of thromboembolic disease, and control cancer-related pain. Nutritional support and optimal replacement therapy in patients with endocrine and/or exocrine insufficiency, is mandatory. This manuscript highlights the most significant problems faced when caring for patients with advanced PDAC and provides an evidence-based approach to symptomatic management.
胰腺导管腺癌(PDAC)是预后最差的癌症之一,是西方国家癌症相关死亡的第三大主要原因。尽管诊断程序和治疗方法有所进步,但在大多数情况下,当疾病局部进展或转移时才被诊断出来。支持性护理旨在改善症状、降低住院率并维持生活质量。适当的对症治疗对于允许化疗和放疗的实施至关重要。对症治疗应该采用多学科的方式进行。其主要目标包括缓解胆道或十二指肠梗阻、预防和/或治疗血栓栓塞性疾病以及控制癌症相关疼痛。对于内分泌和/或外分泌功能不全的患者,必须进行营养支持和最佳替代治疗。本文稿重点介绍了在治疗晚期 PDAC 患者时面临的最重大问题,并提供了一种基于证据的对症管理方法。